[Isoflurane pretreatment reduced liver injury induced by ischemia/reperfusion combined with lipopolysaccharide in rats].
OBJECTIVE
To investigate the effect of lipopolysaccharide (LPS) on ischemia/reperfusion (I/R) injury of liver and the protective effect of isoflurane (ISO) pretreatment on such injury in rat.


METHODS
Thirty-two male Sprague-Dawley(SD) rats were randomly assigned to 4 groups: Sham group, only receive anesthesia and laparotomy; I/R group; I/R+LPS group, with 1 hour of hepatic ischemia and 4 hours of reperfusion, and LPS was given at the beginning of reperfusion; ISO group, received ISO pretreatment for 0.5 hour, then 1 hour of hepatic ischemia followed by 4 hours of reperfusion and LPS given at the beginning of reperfusion. The pathological changes in the liver tissue were assessed. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), the myeloperoxidase (MPO) activity in liver tissue, hepatic and serum tumor necrosis factor-alpha (TNF-alpha) were determined.


RESULTS
Compared with Sham group, ALT, AST, TNF-alpha in serum and MPO activity in liver tissue, hepatic and serum TNF-alpha were increased significantly in all injury groups (all P<0.01). Compared with ISO group alone, hepatic I/R combined with LPS resulted in severer liver injury, with the levels of ALT, AST in serum, MPO activity in the liver tissue, and hepatic and serum TNF-alpha level were all increased (all P<0.05). Compared with I/R+LPS group, both the liver injury and inflammatory reaction were significantly reduced in I/R group (P<0.05 or P<0.01).


CONCLUSIONS
LPS injection during reperfusion results in severer liver injury and inflammatory reaction after hepatic I/R in rats. ISO pretreatment for 30 minutes might reduce the inflammatory reaction and live injury induced by hepatic I/R combined with LPS.
Lv
Xin
X
Department of Anesthesiology, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai 200438, China.
Li
Quan
Q
Huang
Sheng-Dong
SD
Wu
Fei-Xiang
FX
Yang
Li-Qun
LQ
Yu
Wei-Feng
WF
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D004195:Disease Models, Animal; D007530:Isoflurane / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000506:poisoning; D008099:Liver / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D007530:Isoflurane; D000410:Alanine Transaminase